The abstracts can be viewed on the ASCO website www.abstract.asco.org/ConfCatView_114_S.html.
AUY922 is a novel intravenous Hsp90 inhibitor for the treatment of a range of solid tumours. It was the first compound from a collaboration between Vernalis and Novartis to enter clinical testing and has completed phase I trials and is currently in a number of phase II trials. Novartis is conducting and funding future development and Vernalis will receive milestones and royalties on successful development and commercialisation.
Enquiries:
Vernalis Contacts
Ian Garland, Chief Executive Officer
+44 (0) 118 989 9360
David Mackney, Chief Financial Officer
Brunswick Group
Jon Coles
+44 (0) 20 7404 5959
Kristin Shine
Taylor Rafferty
Rob Newman
+44 (0) 20 7614 2900
Faisal Kanth
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.
